Protagonist Therapeutics (Protagonist Therapeutics) ROCE % : 178.23% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Protagonist Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Protagonist Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was 178.23%.

Protagonist Therapeutics ROCE % Historical Data

The historical data trend for Protagonist Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagonist Therapeutics ROCE % Chart

Protagonist Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-66.75

-31.83

-42.81

-50.49

-33.84

Protagonist Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-66.49	-66.35	-51.43	28.86	178.23

Protagonist Therapeutics ROCE % Calculation

Protagonist Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-93.652	/	( ( (247.928 - 31.179)	+	(357.951 - 21.274) )	/ 2 )
	=	-93.652	/	( (216.749	+	336.677)	/ 2 )
	=	-93.652	/	276.713
	=	-33.84 %

Protagonist Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	825.236	/	( ( (357.951 - 21.274)	+	(629.276 - 39.91) )	/ 2 )
	=	825.236	/	( ( 336.677	+	589.366 )	/ 2 )
	=	825.236	/	463.0215
	=	178.23 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Protagonist Therapeutics (NAS:PTGX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Protagonist Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Protagonist Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Protagonist Therapeutics (Protagonist Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagonist Therapeutics Inc (NAS:PTGX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560

Website

https://www.protagonist-inc.com

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Executives

Suneel Gupta	officer: Chief Development Officer	7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Patel Dinesh V Ph D	director, officer: President and CEO	C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Arturo Md Molina	officer: Chief Medical Officer	10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Swisher Daniel N Jr	director	C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Lewis T Williams	director	C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Bryan Giraudo	director	7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Harold E Selick	director
Sarah B. Noonberg	director	331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Sarah A O'dowd	director	3185 LAURELVIEW COURT, FREMONT CA 94538
William D. Waddill	director	C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Asif Ali	officer: Chief Financial Officer	7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Donald A. Kalkofen	officer: Chief Financial Officer	7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
David Y Liu	officer: Chief Scientific Officer	C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Chaitan Phd Khosla	director	3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard S Shame	officer: Chief Medical Officer	C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035